Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT05528302
Active, not recruiting Not applicable

Technology Assisted Cognitive Behavioural Therapy Intervention for Anxiety in People Living With Cognitive Impairment

NCT05528302 · tracked via the Priya Life Science Australia tracker
Sponsor
The University of Queensland
Phase
Not applicable
Started
2023-02-20
Last updated
2026-02-04

Condition(s) studied

DementiaCognitive ImpairmentAnxiety

Investigational drug(s) / intervention(s)

Tech-CBT intervention

Tech-CBT intervention: The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.

Study summary

This study is a randomized controlled trial (RCT) of a remotely-delivered, technology-assisted psychotherapy program, supported by an innovative software platform for people with cognitive impairment experiencing anxiety.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Persons aged 18 years or over * Persons with a diagnosis of mild cognitive impairment (MCI) or dementia of any aetiology based on a previous diagnosis by a clinician or scoring above threshold (≤32; MCI ≤32 and dementia ≤27) for cognitive impairment in the Modified Telephone Interview for Cognitive Impairment (TICS-M). * Screening positive for anxiety (scoring ≥9 on Geriatric Anxiety Inventory, GAI), and/or subjective complaints of anxiety and/ or clinician diagnosis of a current anxiety disorder and screening positive for anxiety using the Rating Anxiety in Dementia scale (scoring ≥11 on RAID) Exclusion Criteria: * Persons with severe dementia * Persons unable to communicate or complete questionnaires * Persons who have a current risk of suicide within the last month as determined by the study clinical expert team. * Persons with major depression as the primary complaint without reported symptoms of anxiety * Persons with comorbid psychiatric conditions

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Queensland University of Technology Brisbane Queensland
Royal Brisbane and Women's Hospital (RBWH), Metro North Hospital and Health Services Brisbane Queensland
Surgical, Treatment and Rehabilitation Services (STARS), Metro North Hospital and Health Services Brisbane Queensland
The University of Queensland Brisbane Queensland
Princess Alexandra Hospital (PAH), Metro South Hospital and Health Services Brisbane Queensland

More The University of Queensland trials in Australia

Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial Starting soon
Pasteurised Donor Human Milk Supplementation for Term Babies Recruiting
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Recruiting
Is Density Spectral Array Display Along With Bispectral Index Superior to the Display of Bispectral Index Alone Starting soon
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment Recruiting

Other trials for the same condition

Retinal Hyperspectral Imaging in Neurodegenerative Diseases Recruiting
Sleep and Stress Study Recruiting
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis Recruiting
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial Active, not recruiting
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05528302 on ClinicalTrials.gov ↗ ← All trials in Australia